A two-year old patient at the Royal Manchester Children’s Hospital (RMCH) is the first in the world to receive a pioneering new gene therapy treatment for the rare and life-limiting genetic condition, Mucopolysaccharidosis IIIA (MPSIIIA). The treatment was manufactured at Great Ormond Street Hospital (GOSH) and the UCL Great Ormond Street Institute of Child Health (ICH) after being developed by RMCH and the University of Manchester.
A team from University College London Hospitals (UCLH), UCL and Great Ormond Street Hospital (GOSH) has won the clinical leadership team award in the BMJ awards, the UK's leading medical awards which promote excellence in healthcare and recognise the inspirational work of healthcare teams across the country.
Over 150 people came along to the National Institute for Health Research (NIHR) GOSH Biomedical Research Centre showcase last month to hear about our latest research highlights - from cutting edge CAR-T therapies for leukaemia, to Oculome genomic sequencing to diagnose rare childhood eye conditions.
GOSH and UCL Great Ormond Street Institute of Child Health (ICH) researchers Professor Paul Gissen and Dr Julien Baruteau will be part of a new collaboration with Evox Therapeutics that aims to develop a new therapy for the life threatening metabolic condition, argininosuccinic aciduria (ASA)
Over 30 nurses and allied health professionals (AHPs) attended a training weekend hosted by GOSH’s Centre for Outcomes and Experience Research in Children’s Health Illness and Disability (ORCHID) earlier this month.